Mary Wise, NP
Primary Care · Milwaukee, WINPI 1558502153
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations.
Across 82 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$391
- Teva Pharmaceuticals USA, Inc.$196
- Neurocrine Biosciences, Inc.$128
- AstraZeneca$125
- Gilead$123
- Boehringer Ingelheim$121
- plus $608 from 13 others
What the payments were for
- Food & beverage$1,692100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 41 | $391 |
| Teva Pharmaceuticals USA, Inc. | 5 | $196 |
| Neurocrine Biosciences, Inc. | 2 | $128 |
| AstraZeneca | 1 | $125 |
| Gilead | 2 | $123 |
| Boehringer Ingelheim | 6 | $121 |
| Axsome Therapeutics, Inc. | 1 | $117 |
| Pfizer | 4 | $88 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| AbbVie | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Ironwood Pharmaceuticals, Inc | 3 | $45 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| Agile Therapeutics, Inc. | 2 | $36 |
| Alkermes, Inc. | 1 | $34 |
| Lundbeck LLC | 1 | $22 |
| Merck | 1 | $17 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- Austedo XR$125
- Auvelity$117
- Epclusa$107
- INGREZZA$107
How this compares
$1,692 in reported general payments places this provider in the 85th percentile of 52 primary care providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 26 | $31,002 |
| JanuviaSitagliptin Phosphate | 32 | $25,881 |
| LinzessLinaclotide | 17 | $15,964 |
| XareltoRivaroxaban | 17 | $15,014 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $9,614 |
| EliquisApixaban | 15 | $9,382 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 14 | $5,408 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $2,959 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 106 | $2,737 |
| Atorvastatin Calcium | 282 | $2,172 |
| Ventolin HfaAlbuterol Sulfate | 24 | $1,610 |
| Lidocaine | 22 | $1,304 |
| Amlodipine Besylate | 208 | $1,057 |
| Metformin Hcl | 131 | $727 |
| Losartan Potassium | 100 | $698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet Xr | $17 | $35,49643 claims |
| Boehringer IngelheimJardiance | $121 | $31,00226 claims |
| AbbVieLinzess | $51 | $15,96417 claims |
| Johnson & JohnsonXarelto | $391 | $15,01417 claims |
| PfizerEliquis | $88 | $9,38215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 52 primary care providers in Wisconsin.
Other primary care in Milwaukee
- Michael PotnekMilwaukee$71K
- Kelly StoneMilwaukee$2K
- Courtney LammMilwaukee$2K
- Alexandra KochMilwaukee$525
- Jana ZullnerMilwaukee$461
- Lisa KorbanMilwaukee$301
- Heejin KwonMilwaukee$267
- Lauren NewellMilwaukee$243
- Cheryl GatesMilwaukee$120
- Blanca BobadillaMilwaukee$107
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.